@article{oai:repo.qst.go.jp:00084610,
 author = {Yoichi, Takakusagi and Aya, Sugyo and Atsushi, Tsuji and Hitomi, Sudo and Yasunaga, Masahiro and Matsumura, Yasuhiro and Sugawara, Fumio and Sakaguchi, Kengo and Tatsuya, Higashi and Yoichi, Takakusagi and Aya, Sugyo and Atsushi, Tsuji and Hitomi, Sudo and Tatsuya, Higashi},
 issue = {1},
 journal = {Translational Oncology},
 month = {Jan},
 note = {α-Sulfoquinovosylacyl-1,3-propanediol (SQAP) is a semi-synthetic derivative of natural sulfoglycolipid that sensitizes tumors to external-beam radiotherapy. How SQAP affects internal radiotherapy, however, is not known. Here, we investigated the effects of SQAP for radioimmunotherapy (RIT) targeting tissue factor (TF) in a stroma-rich pancreatic cancer mouse model, BxPC-3. A low dose of SQAP (2 mg/kg) increased tumor uptake of the 111In-labeled anti-TF antibody 1849, indicating increased tumor perfusion. The addition of SQAP enhanced the growth-inhibitory effect of 90Y-labeled 1849 without leading to severe body weight changes, allowing for the dose of 90Y-labeled 1849 to be reduced to half that when used alone. Histologic analysis revealed few necrotic and apoptotic cells, but Ki-67–positive proliferating cells and increased vascular formation were detected. These results suggest that the addition of a low dose of SQAP may improve the therapeutic efficacy of TF-targeted RIT by increasing tumor perfusion, even for stroma-rich refractory pancreatic cancer.},
 title = {The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3},
 volume = {15},
 year = {2022}
}